Deciphera Pharmaceuticals Board of Managers

James A. Bristol is Co-Chairman of the managing board. Dr. Bristol recently retired from Pfizer, Inc., where he held the position of Senior Vice President, Worldwide Discovery Research from 2003-2007. Prior to this position, he was Vice President, Discovery Research, at the Pfizer Global Research & Development site in Ann Arbor, Michigan from 2000-2003. Dr. Bristol was also with the Parke-Davis Pharmaceutical Resarch Division of Warner-Lambert from 1980-2000, where he rose through leadership positions culminating as Vice President, Discovery Research. Dr. Bristol has also exhibited outstanding leadership in the pharmaceutical and medicinal chemistry community, exemplified by serving on the Gordon Research Conferences Board of Trustees (1998 - 2004), serving as Editor in Chief, Annual Reports in Medicinal Chemistry, Academic Press (1990 - 1998), Senior. Editor, Current Opinion in the Chemistry of Drug Discovery and Development, (1998 - present), and serving leadership roles in the American Chemical Society Division of Medicinal Chemistry, including National Chairman of the division during 1995. Dr. Bristol has 46 publications in peer-reviewed journals and 30 granted U.S. patents. In recognition of his service to the pharma industry, Dr. Bristol received the American Chemical Society's Earle B. Barnes Award for Leadership in Chemical Research Management in 2004.

Daniel L. Flynn is President and CEO of the company. He received his PhD in medicinal chemistry at the University of Kansas in 1981. After completing a post-doctorate in synthetic organic chemistry at Indiana University, he joined Warner-Lambert/Parke Davis Pharmaceuticals in Ann Arbor, Michigan, in 1983. In 1988, he moved to Searle Pharmaceuticals in Skokie, IL and later St. Louis, MO. In his ten year period with Searle, he brought over five compounds into preclinical development, and advanced 3 drugs into clinical trials, including Xemilofiban and Orbofiban. He invented and developed a major platform in combinatorial chemistry now known as "phase-trafficking" synthesis. In 1998, Dan joined Amgen, Inc in Thousand Oaks, CA, as Director of Medicinal Chemistry. In 2000, he moved to Cambridge, MA, as Senior Director of Chemistry with Millennium Pharmaceuticals. While at Millennium Pharmaceuticals, Dan managed the medicinal chemistry that resulted in the delivery of an anti-obesity drug into human clinical trials. Dan is Adjunct Professor of Medicinal Chemistry at the University of Kansas-Lawrence and served as the national Chair for the Division of Medicinal Chemistry of the American Chemical Society.

Harold Jacobi, III graduated from the University of Virginia with a B.A. in 1967 and The Boston University School of Law with a Juris Doctorate in 1970. Mr. Jacobi is the founder and principal of Jacobi & Associates with offices in downtown Boston, Lexington, and Situate, Massachusetts. Mr. Jacobi has practiced law in Massachusetts for the past 33 years. His areas of expertise are corporate law and business litigation. Mr. Jacobi has served as incorporator, clerk, director and corporate counsel to corporations, LLC’s and other business entities. He has extensive experience in banking, real estate, business and insurance law. He has served for five years as the Vice President of the Massachusetts Trial Lawyers Association. Mr. Jacobi serves as a director for a number of corporations and non-profit organizations, notably International Center for Religion and Diplomacy with offices in Washington, D.C.

Ben McCallister, M.D. is the Endowed Chair and Director of Cardiovascular Research at the Mid America Heart Institute, Saint Luke's Hospital of Kansas City, and is a Professor of Medicine at the University of Missouri-Kansas City School of Medicine. Dr. McCallister received his B.A. and M.D. degrees from the University of Kansas. His initial career was at the Mayo Clinic from 1961-69 after serving in the U.S. Army as a Captain in the Medical Corps from 1957-61. He completed a Fellowship in cardiology and was a National Institutes of Health Research Fellow. He subsequently served as a consultant in cardiovascular diseases and internal medicine at the Mayo Clinic prior to joining the staff at Saint Luke's Hospital of Kansas City in 1970. Since that time, he has been a Consultant in Cardiovascular Diseases at the Mid America Heart Institute of Saint Luke's Hospital and has had various leadership positions at the Mid America Heart Institute, including Chairman of the Department of Cardiovascular Diseases. He was instrumental in the development of the Mid America Heart Institute and was Vice Chairman of the MAHI Advisory Board from 1975-1999.

Timothy S. Sotos is Co-Chairman of the managing board. He is also Chairman/CEO of Clinical Reference Laboratory, Inc. Mr Sotos received a B.S. Economics and M.B.A. from the Wharton School, University of Pennsylvania. He has over 30 years consulting and management experience with positions at Ernst and Young (formerly Arthur Young and Company), and two Fortune 500 companies.

Deciphera Pharmaceuticals, LLC
4950 Research Park Way
Lawrence, KS 66047

785-838-3767 phone
785-838-3747 fax
info@deciphera.com

Copyright © Deciphera Pharmaceuticals, LLC 2002-2009
All Rights Reserved